Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease

HIV Clinical Trial

Official title:

Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02058719
• Other study ID #: 13-2986
• Status: Completed
• Start date: March 2014
• Est. completion date: December 2019

Study information

• Verified date: December 2019
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study plans to learn more about pulmonary complications of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Even though antiretroviral therapy (ART) has dramatically decreased the number of opportunistic infections and deaths in HIV infected patients, pulmonary complications (including chronic obstructive pulmonary disease (COPD) development and pneumonias resulting in decreased lung function) of HIV/AIDS continue to be a major cause of morbidity and mortality in this population. The mechanisms underlying the increased risk of COPD and decreased lung function in HIV infected individuals is not well understand and needs to be studied.

The investigators hypothesize that the immunoregulatory consequences and immunosuppressive lung milieu secondary to HIV and cigarette smoke combine to increase the risk of lung infection and injury in HIV infected smokers, hastening the development of COPD. The mechanisms will be directly tested using blood and bronchial alveolar lavage (BAL) cells from smokers and nonsmokers with and without HIV infection.

Description:

The first component of this study will be a longitudinal, prospective, 24 weeks study of the effects of HIV-1 infection on innate and acquired immunity in the lung (Cohort A). The second component of this study will be a cross-sectional, case-control study of lung function and immune dysregulation of HIV-1 infected persons on long-term ART (Cohort B).

Cohort A will consist of 120 subjects, stratified by HIV-1 and smoking status

Cohort B will consist of 90 subjects stratified by chronic obstructive pulmonary disease (COPD) and HIV-1 infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 210
• Est. completion date: December 2019
• Est. primary completion date: July 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria (Cohort A):

• Subjects with chronic HIV-1 infection (Cohorts A1 and A2)

• ART naïve or off all ART for >6 months (Cohorts A1 and A2)

• HIV-1 RNA level >1,000 copies/ml (Cohorts A1 and A2)

• HIV-1 seronegative with no high-risk exposure in the past 30 days (Cohorts A3 and A4)

• 18 years and older (All Cohort A)

• Active cigarette smoker (Cohorts A1 and A3)

Inclusion Criteria (Cohort B):

• Age from 30 to 70 years

• Subjects with chronic HIV-1 infection (Cohorts B1 and B2)

• Subjects on stable 3-drug ART regimen with plasma HIV-1 RNA <50 copies/mL for past 6 months (Cohorts B1 and B2)

• HIV-1 seronegative with no high-risk exposure in the past 30 days (Cohort B3) COPD:

forced expiratory volume at one second (FEV1)/forced vital capacity (FVC) <70% and forced expiratory volume (FEV), 45-100% of predicted (Cohort B1 and B3)

• Non-COPD: FEV/FVC >70% and an FEV, >80% of predicted (Cohort B2)

Exclusion Criteria (Cohort A and B):

• Pregnancy

• Weight less than 110 pounds (for venipuncture)

• Patient inability to participate in the study and undergo venipuncture and bronchoscopy procedures

• Use of systemic or inhaled corticosteroids in the past 3 months.

Related Conditions & MeSH terms

• COPD
• HIV
• Lung Diseases
• Smoking

Locations

Country	Name	City	State
United States	University of Colorado Denver	Aurora	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change in immunoregulatory markers: PD-1 expression and interleukin (IL)-10 production by alveolar macrophages (AMs) from baseline to week 24.	Evaluate the immunoregulatory change between HIV positive (smokers/non-smokers) and HIV negative (smokers/non-smokers)	Baseline, Week 24
Primary	PD-1 expression and IL-10 production by AMs at baseline	Evaluate the association of PD-1 expression and IL-10 production by AMs after long-term antiretroviral therapy (ART) with abnormal lung function and a COPD phenotype between HIV positive (with and without COPD) and HIV negative with COPD.	Baseline